Red blood cell phenotype prevalence in blood donors who self-identify as Hispanic by Sheppard, Chelsea A. et al.
IMMUNOHEMATOLOGY, Volume 33, Number 3, 2017 119
Red blood cell phenotype prevalence in blood 
donors who self-identify as Hispanic
C.A. Sheppard, N.L. Bolen, B. Eades, G. Ochoa-Garay, and M.H. Yazer
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Molecular genotyping platforms provide a quick, high-throughput 
method for identifying red blood cell units for patients on 
extended phenotype-matching protocols, such as those with 
sickle cell disease or thalassemia. Most of the antigen prevalence 
data reported are for non-Hispanic populations. Therefore, 
this study sought to determine the phenotype prevalence in a 
single blood center’s Hispanic population and to compare those 
results with previously reported rates in non-Hispanic donor 
populations. We performed a retrospective review of all serologic 
and molecular typing from donors who self-reported as Hispanic. 
The phenotype prevalence was reported and compared with rates 
from other racial/ethnic groups. A total of 1127 donors who self-
identified as Hispanic were screened by serologic methods for 
Rh and Kell antigens, and 326 were subsequently selected for 
molecular typing. The most prevalent probable Rh phenotypes 
were R1r (26.6%), R1R2 (21.5%), and R1R1 (20.7%); rr was found in 
7.8 percent of donors tested. The percentage of K+ donors in this 
population was 2.8 percent. The most prevalent Duffy phenotypes 
were Fy(a+b+) (35.9%), Fy(a+b–) (35.6%), and Fy(a–b+) (27%). Of 
the donors studied, 15.3 percent had an FY GATA mutation. Only 
1.5 percent of the donors were Fy(a–b–). The Jk(a+b+) phenotype 
was found in nearly half of the population. M+N+S+s+ was the 
most prevalent MNS phenotype from that group, constituting 
22.4 percent. A total of 95.7 percent of the donors were Lu(a–b+), 
and Di(a–b+) was observed in 94.4 percent. The most prevalent 
Dombrock phenotype was Do(a+b+), constituting 46.9 percent, 
followed closely by Do(a–b+) at 40.5 percent. Hispanic donor 
antigen prevalence is distinctly different from other racial/ethnic 
groups and should be considered when attempting to find extended 
matched units for these patients. Immunohematology 2017; 
33:119–124.
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Molecular testing of donors has become an increasingly 
common strategy to provide antigen negative units for patients 
(1) on chronic transfusion protocols at risk for alloimmuniza-
tion (e.g., patients with sickle cell disease [SCD]), (2) for whom 
a complete serologic evaluation is labor-intensive and time-
consuming (e.g., those with warm autoantibodies), or (3) 
requiring immunohematologic evaluations that are logistically 
difficult (e.g., recently transfused patients or those with 
antibodies for which serologic reagents are not commercially 
available). Molecular testing of donors has provided a rapid, 
high-throughput method for predicting the donors’ extended 
phenotypes.
Genotyping the entire donor population is not as yet 
efficient or economical, however. Requests for antigen-negative 
units in the United States come primarily for the treatment of 
patients with SCD who are at risk for alloimmunization. Many 
blood centers have therefore concentrated their efforts on the 
recruitment, collection, and genotyping of black donors who 
are more likely to be antigenically similar to patients with 
SCD. Thus, many of the reported antigen prevalence rates 
are from the African American (or black) and Caucasian (or 
white) populations. There are only a few studies that report 
antigen prevalence rates for Hispanics.1,2 According to the 
2010 U.S. Census, Hispanics constitute 16.3 percent of the 
U.S. population—as such, they are the fastest-growing group. 
Thus, antigen prevalence rates among this group will likely be 
more necessary in the years to come. This report describes 
antigen prevalence in a large cohort of donors who self-identify 
as Hispanic.
Materials and Methods
This is a retrospective study of serologic and molecular 
testing for red blood cell (RBC) antigens in self-identified 
Hispanic volunteer blood donors who were tested from 2008 to 
2016 at a large regional blood collection center (Virginia Blood 
Services [VBS], Richmond, VA). VBS has over 80,000 RBC 
donors annually. VBS donors are asked during registration 
to self-identify their race/ethnicity, which is recorded on their 
health history form. The donor is then asked to confirm the 
accuracy of the form at every subsequent donation. Donors 
can self-identify as Caucasian/white, African American/
black, Asian, American Indian, Middle Eastern/East Indian, 
Hispanic, or other (for donors who self-identify with more 
than one choice). There is also an option to leave the race 
category blank, although fewer than 0.2 percent of donors 
choose this option. From 2008 to the present, approximately 
80 percent of these presenting donors self-identified as 
Caucasian. In the same time period, donors who self-identified 
as African American or black constituted 13–14 percent of the 
total. In 2008, only 1 percent of VBS donors self-identified as 
Hispanic. In the most recent fiscal year, however, 2.32 percent 
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of these presenting donors self-identified as Hispanic. A query 
was run in the VBS Laboratory Information System/Blood 
Establishment Computer System (LIS/BECS) (Blood Bank 
Computer Systems, Inc., Auburn, WA) for units from Hispanic 
donors with historic serologic and molecular testing results. 
The phenotype prevalence from this query is reported here.
The method for typing donors at the Institute for 
Transfusion Medicine Clinical Services Immunohematology 
Reference Laboratory (IRL) in Richmond, Virginia, was as 
follows (Fig. 1): A daily report was run from the LIS for all 
donors who presented that day. First-time, self-identified 
black or group O, D+ or O, D– non-Caucasian donors were 
selected and screened using a microplate method described 
in Immunohematology Methods and Procedures3 using Bio-
Rad reagents (Dreieich, Germany) for C, E, c, e, and K. Donors 
were selected for genotyping if their serologic testing indicated 
them to be K– and R1R1, R2R2, R0r, or rr. DNA was extracted 
using QIAcube (QIAGEN, Hilden, Germany). Genotyping 
was performed, according to the manufacturer’s instructions, 
using human erythrocyte antigen (HEA) BeadChip DNA 
array (BioArray/Immucor, Warren, NJ) from 2008 to 2014, 
and ID CORE XT (Progenika Biopharma/Grifols, Derio, 
Spain) from 2014 to March 2016. The difference between the 
two platforms is outside the scope of this report because only 
antigens tested by both platforms were reported in this study. 
The only exception is a small number of donors with RHCE 
variants, which were detected by ID Core XT; therefore, we 
did describe the variants detected by this assay. Rh phenotype 
prevalence rates were calculated from both the serologic result, 
for donors who did not qualify for molecular typing (Table 1), 
and the molecular result for those who qualified (Table 2). If a 
discrepancy between the serology and the molecular results 
was identified at the time of testing, it was investigated, 
resolved, and recorded in the LIS at that time. Thus, the 
data reviewed in this retrospective study will only include 
the resolved type. The phenotype prevalence rates from our 
Hispanic population are reported in Tables 1 and 2 and are 
compared with those listed in the most recent edition of The 
Blood Group Antigens Factsbook.4
Results
In total, 1127 unique donors who self-identified as Hispanic 
were screened by serology and thus had results reported in the 
LIS/BECS. Molecular testing was performed on 326 of these 
1127 donors (those who met the qualifications for molecular 
typing); specifically, 124 of 326 (38%) donors were typed 
using BeadChip DNA array (Immucor), and 202 of 326 (62%) 
were typed using ID CORE XT (Progenika Biopharma).
A total of 1127 donors who self-identified as Hispanic were 
screened serologically for Rh antigens, and 1125 donors were 
also screened for K (2 of the 1127 donors were not screened for 
K for unknown reasons, but likely because of a limited amount 
of reagent available at the time). The phenotype prevalence of 
the antigens in the Rh blood group system and for K is listed in 
Table 1. The k (Cellano) antigen phenotype prevalence was not 
evaluated because only K– units were selected for molecular 
testing.
Several Rh variants were identified among the 202 donors 
tested by the ID CORE XT platform. All Rh variant data were 
from donors tested using the ID CORE XT (hrB status was 
not available with the basic BeadChip assay and was thus not 
further investigated unless required for patient care). In 9 of 
202 (4.5%) of these donors, the RHCE*ce[733G] allele (c.733G, 
c.712A, c.1006G) was identified. Thus, the prevalence of V+ in 
this population also was 4.5 percent. Only 1 of the 202 (0.5%) 
donors was homozygous for the c.733G single nucleotide 
polymorphism (SNP) (predicting V+/VS+) associated with 
loss of the high-prevalence hrB antigen; 8 of 202 (4%) were 
heterozygous for this variant.
1127 Hispanic donors were 
screened by microplate*
124 tested with  
HEA BeadChip DNA Array
All discrepancies between 
serology and molecular 
testing are investigated 
and resolved at the time of 
testing. Results are entered 
into LIS
202 tested with  
ID CORE XT
Results are confirmed  
and entered into LIS
326 K– and qualifying  
Rh† proceeded to  
molecular tesing
891 K+ or non-qualifying 
Rh did NOT proceed to 
molecular testing
Fig. 1 Method for obtaining historical antigen data. *Microplate 
screening selection: all first-time, hemoglobin S–negative, black 
donors, or group O, D+ or O, D– non-Caucasian donors. Initial 
serologic screening for C, E, c, and K. Donors who screen as C–, 
E+, and c+ are subsequently tested for e. †Qualifying Rh = R0r, R1R1, 
R2R2, or rr. HEA = human erythrocyte antigen; LIS = laboratory 
information system.
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The phenotypic prevalence of Jsa, Kpa, and antigens in 
the Duffy, Kidd, MNS, Lutheran, Diego, and Dombrock blood 
group systems are shown in Table 2. In addition to these 
results, a total of 15.3 percent of the donors studied had an 
FY GATA mutation. Of these, 9.5 percent were either FY*B_
GATA, FY*A or FY*B_GATA homozygous. Only 1.2 percent (4 
of 326) had the point mutation in the FYB gene leading to the 
Fyx phenotype and conferring weak Fyb expression; however, 
2.1 percent had a single variant allele. In the Kidd blood group 
system, one donor expressed a JK*B(IVS5-1A) variant allele, 
which is rarely seen except in individuals of Asian or Polynesian 
descent. In the MNS blood group system, a single donor had 
a GYPB*S(IVS5+5T) variant allele that is commonly seen in 
the black population. Di(a+) comprised 5.6 percent (18 of 324; 
2 results were indeterminate and so not included) of the self-
identified Hispanic donors. Finally, 3 percent of these donors 
had a rare Dombrock allele, although all were heterozygous 
for this allele. Three (0.9%) donors had a variant DO*JO allele; 
seven (2.1%) had a variant DO*HY allele.
Discussion
Although Hispanics make up approximately 16 percent of 
the U.S. population per recent Census reporting, they constitute 
about 2.32 percent of our presenting donor population. This is, 
however, more than a 100 percent increase since 2008. With 
the demographics of the United States changing rapidly, it is 
important that we understand the phenotypic prevalence of 
RBC antigens in this growing demographic. This study was a 
retrospective review of serologic and molecular testing results 
from 1127 self-identified Hispanic donors tested between 
2008 and March 2016.
The Rh haplotypes for the self-identified Hispanic 
population are similar to those of Caucasians in that R1r 
and R1R1 are the most common phenotypes. Additionally, 
the most common phenotype for African Americans (R0r), 
which has been reported to occur in about 45.8 percent of that 
population, comprises only 5.6 percent of these study donors.3 
The RHCE*ce[733G] allele, however, which is common in 
black (26–40%) and uncommon in Caucasians (<0.01%), is 
seen in 4.5 percent of the study donors. Because this allele is 
associated with the VS and V antigens, the prevalence of VS+V+ 
in this self-identified Hispanic population is also 4.5 percent. 
The prevalence of V in the Caucasian and black populations is 
1 percent and 30 percent, respectively.
We assumed that most donors would be e+, primarily 
when the donor typed as C+. It is possible that some of these 
donors are actually e–. For example, of the donors who were 
typed for e (484 of 1127, 43%), those who were R1R2 made 
up 21.5 percent of the study population, and those who were 
R2Rz made up 0.3 percent. This prevalence is similar to that 
reported in other races/ethnicities with R1R2 prevalence 
Table 1. Phenotype prevalence for self-identified Hispanic donors compared with other reported races/ethnicities: results from 1127 
donors screened by microplate system*
Percent occurrence†
Phenotype Hispanic N = 1127 (%) Caucasian Black Asian
R1R1 (R1r') 233 (20.7) 18.5 2.0 51.8
R2R2 (R2r") 50 (4.4) 2.3 0.2 4.4
R1r (R1R0; R0r') 300 (26.6) 34.9 21 8.5
R2r (R2R0; R0r") 123 (10.9) 11.8 18.6 2.5
R0r (R0R0) 63 (5.6) 2.1 45.8 0.3
R1R2 (R1r"; R2r'; Rzr; R0Rz; R0ry) 242 (21.5) 13.3 4.0 30.0
R1Rz 19 (1.7) 0.0 Rare 1.4
R2Rz 3 (0.3) 0.1 Rare 0.4
rr 88 (7.8) 15.1 6.8 0.1
r'r 7 (0.6) 0.8 Rare 0.1
r"r 2 (0.2) 0.9 Rare Rare
r'r" 1 (0.08) 0.05 Rare Rare
V+ 9 (4.5)‡ 1 30 NA
K+ 31 (2.8)§ 9 2 NA
*A total of 645 of 1127 donors (57%) were assumed e+ and were not actually tested for e.
†Non-Hispanic percent occurrence retrieved from Reid et al.4
‡Only molecular results available from ID CORE XT (N = 202).
§N = 1125.
NA = not available.
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as follows: Caucasian = 13.3 percent, blacks = 4.0 percent, 
Asians = 30 percent, and R2Rz prevalence: Caucasian = 0.1 
percent, blacks = rare, Asians = 0.4 percent. Because of this 
assumption, the prevalence of R1R2 might be slightly lower, 
and the prevalence of R2Rz slightly higher, but we believe the 
change would be insignificant.
As mentioned earlier, 2.8 percent of this self-identified 
Hispanic population was K+. This prevalence is similar to 
C.A. Sheppard et al.
Table 2. Phenotype prevalence for self-identified Hispanic donors compared with other reported races/ethnicities: results from 326 
donors by molecular testing
Percent occurrence*
Phenotype Hispanic, N = 326 (%) Caucasian Black Chinese Japanese Thai
Fy(a+b–) 116 (35.6) 17 9.0 90.8 81.5 69
Fy(a–b+) 88 (27) 34 22 0.3 0.9 3
Fy(a+b+) 117 (35.9) 49 1 8.9 17.6 28
Fy(a–b–) 5 (1.5) Very rare 68 0 0 0
Fyb [GATA], Fya 26 (8) NA NA NA NA NA
Fyb [GATA], Fyb 19 (5.8) NA NA NA NA NA
Fyb [GATA] homozygous 5 (1.5) NA NA NA NA NA
Fyx† 4 (1.2) NA NA NA NA NA
Hispanic Caucasian Black
Kp(a+b+) 4 (1.2) 2.3 Rare
Kp(a–b+) 322 (98.8) 97.7 100
Js(a+b+) 9 (2.8) Rare 19
Js(a–b+) 317 (97.2) 100 80
Hispanic Caucasian Black Asian
Jk(a+b–) 87 (26.7) 26.3 51.1 23.2
Jk(a–b+) 77 (23.6) 23.4 8.1 26.8
Jk(a+b+) 162 (49.7) 50.3 40.8 49.1
Hispanic Caucasian Black
M+N–S+s– 22 (6.8) 6 2.0
M+N–S+s+ 65 (19.9) 14 7
M+N–S–s+ 40 (12.3) 8 16
M+N+S+s– 13 (4) 4 2
M+N+S+s+ 73 (22.4) 24 13
M+N+S–s+ 64 (19.6) 22 33
M–N+S+s– 4 (1.2) 1 2
M–N+S+s+ 13 (4) 6 5
M–N+S–s+ 31 (9.5) 15 19
M+N–S–s– 1 (0.3) 0 0.4
Hispanic Most populations
Lu(a+b+) 14 (4.3) 7.4
Lu(a–b+) 312 (95.7) 92.4
Hispanic Caucasian Black Asian South American Indian
Di(a+b+) 18 (5.6) <0.1 <0.1 10 36
Di(a–b+) 308 (94.4) >99.9 >99.9 90 64
Hispanic Caucasian Black Japanese Thai
Do(a+b+)Hy+Jo(a+) 153 (46.9) 49 44 22 13
Do(a–b+)Hy+Jo(a+) 132 (40.5) 33 45 76.5 86.5
Do(a+b–)Hy+Jo(a+) 41 (12.6) 18 11 1.5 0.5
*Non-Hispanic percent occurrence retrieved from Reid et al.4
†2.1 percent had the variant Fyx allele.
NA = not available.
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that seen in the black population (2% vs 9% in the Caucasian 
population). Additionally, in the Kell system, Js(a+) has a 
population prevalence of less than 0.1 percent in Caucasian 
individuals and 20 percent in black individuals. We found a 
prevalence of 2.8 percent in our Hispanic donor population. 
Kp(a+) was also seen in 1.2 percent of our sample population, 
compared with 2 percent in Caucasian individuals and less 
than 0.01 percent in black individuals.
One of the successes of molecular testing was the 
identification of the FY promoter silencing mutation (67T>C, 
FY*01N.01 allele), which is common in blacks but rare in 
Caucasian populations. This mutation silences expression of 
Fyb on RBCs, but Fyb expression on other tissues is preserved, 
thus mitigating the need for Fy(b–) RBCs. A recent study 
by Wilkinson et al.5 found that 96.8 percent (61 of 63) of 
patients with SCD had a GATA mutation: 60.3 percent (38 
of 63) were FY*02-GATA-67 homozygous (FY*B_GATA 
homozygous), and 36.5 percent (23 of 63) were FY*01/02-
GATA-67 heterozygous (FY*B_GATA, FY*A). Alternatively, 
only 17 percent of Caucasians type Fy(a+b–), and far less than 
1 percent are Fy(a–b–). Additionally, the GATA mutation is 
exceedingly rare in Caucasians. In this study population, 15 
percent (50 of 326) had the GATA mutation, and over half 
(52%, 26 of 50) were FY*01/02-GATA-67C heterozygous 
(FY*B_GATA, FY*A). Only 10 percent (5 of 50) were FY*02-
GATA-67C homozygous, and 38 percent (19 of 50) were 
FY*02/02-GATA-67C (FY*B_GATA, FY*B). Thus, unlike the 
black population, most Hispanic donors with an FY*B_GATA 
mutation were also Fy(a+) (52%). This phenotype prevalence 
was very similar to another study that evaluated phenotypes 
of Hispanic individuals in South Texas.1
Additionally, FY*B[265T]FY*X, which results in weak Fyb 
expression, is more common in Caucasians than in blacks and 
was found in four of our donors (1.2%, 4 of 326).
Dia and Dib are antithetical antigens. Dia is a low-
prevalence antigen with an occurrence of 0.01 percent in 
most populations, although it has a much higher prevalence 
in certain South American Indian groups. It is also reported 
to occur in 1 percent of Hispanic populations. However, 5.8 
percent of our study donors were Di(a+). This is lower than the 
rate reported by Moulds and Alperin in Mexican Americans 
living in three Texas communities (14.7%, 8.9%, and 8.2%, 
respectively).6
Homozygosity for DO*HY and DO*JO [resulting in Hy− or 
Jo(a−) phenotypes, respectively] are found rarely in the Black 
population and never in the Caucasian population. We found 1 
percent and 1.5 percent of these Hispanic donors had DO*HY 
and DO*JO alleles, respectively. Our donors were heterozygous, 
however. The data on the frequency of heterozygosity for these 
alleles are not published, to our knowledge.
Using racial self-identification when selecting donors to 
genotype may efficiently find donors who are more likely to 
“match” patients—although genetic variability between and 
even within racial groups is considerable.7 Self-identification 
often serves as a proxy for genetic ancestry, but it may not 
correspond well with genetic ancestry, especially in the 
Hispanic population, because of the broad definition of the 
term and reporting biases of the individuals.8–10 According 
to the U.S. Office of Management and Budget, the term 
Hispanic used in the 2010 Census “refers to a person of 
Cuban, Mexican, Puerto Rican, South or Central American, or 
other Spanish culture regardless of race.”11 As a result of this 
inclusive definition, a large limitation of this study is whether 
the data collected from donors who self-identify as Hispanic 
truly represent a “Hispanic” phenotype, or if one even exists. 
Additionally, although an individual may acknowledge 
multiple genetic ancestries, he/she may not identify with and 
therefore report the corresponding racial group. As such, self-
reported ethnicity/race may be an effective tool for screening 
donors to genotype, but is likely insufficient for mitigating 
alloimmunization.
Additionally, the Hispanic population constitutes the 
second largest group of patients affected by SCD in the United 
States. According to the U.S. Centers for Disease Control 
and Prevention, “SCD occurs among about 1 out of every 
16,300 Hispanic-American births.”12 Extended phenotype-
matching transfusion protocols have been used to reduce 
alloimmunization and the complications of such in black 
patients with SCD.13–15 It may also mitigate alloimmunization 
in the Hispanic population as well.
Finally, RBC genotyping has shown high concordance 
between molecular and serologic results, and thus it has been 
proposed that historic molecular results be used to issue units 
without serologic confirmation.16 The implementation of this 
proposal would greatly increase the application of donor typing 
by molecular methods and thus the practice of genotyping 
donors.
In conclusion, the U.S. Hispanic population as is currently 
defined appears to be phenotypically unique in the expression 
of clinically significant and commonly identified RBC 
antigens. Additionally, Hispanic donors occasionally express 
variant alleles seen in other racial/ethnic groups, but typically 
in different frequencies. Thus, as the U.S. Hispanic population 
increases, the need for antigenically similar blood will likely 
continue to increase. This report provides one center’s 
experience with such a population.
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